Skip to main content
Top
Published in: Journal of Neurology 9/2006

01-09-2006 | LETTER TO THE EDITORS

Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin’s disease

Authors: M. T. Ferrò, T. Riccardi, A. Montanelli, P. Bernasconi, R. Mantegazza

Published in: Journal of Neurology | Issue 9/2006

Login to get access

Excerpt

Sirs: We report a case of thymic Hodgkin’s disease (HD) in a patient with sero-positive generalized myasthenia gravis (MG) whose successful treatment for HD was associated with reduction of anti-acetylcholine receptor antibodies (anti-AChR-ab) and a complete remission of myasthenic symptoms. The female patient developed MG at the age of 52; the diagnosis was in accordance with clinical, pharmacological and electrophysiological criteria; anti-AChR-ab were 21.3 pmoles/ml. Chest CT and MRI suggested the presence of a thymoma, though anti-titin and anti-ryanodine receptor (RyR) antibody detection was negative. In January 1995, the patient began anticholinesterase and immunosuppressive treatment (prednisone and azathioprine) and a clinical improvement was observed. In December 1995 she was thymectomized by Video Assisted Thoracoscopic Extended Thymectomy without sternotomy [1]. Pre-tracheal, anterior mediastinal and costo-phrenic fat plus a thymic residue with a 1.5 cm diameter mass were removed; histological examination revealed an unexpected nodular sclerosing syncytial Hodgkin’s lymphoma within an involuted thymus. Total-body CT and bone marrow biopsy confirmed a clinically stage II A HD with mediastinal bulk. In February 1996, immunosuppressants were discontinued and adriamycin (90 mg) plus vinblastine (11 mg) started. Chemotherapy was temporary interrupted after 3 sessions owing to the onset of serious side effects; it was then resumed in May 1996 (5 cycles of low doses of adriamycin-bleomycin-vinblastine-dacarbazine) followed by mediastinal radiotherapy (30 gray plus a burst 10 gray) 6 months after. Clinical follow-up demonstrated a complete remission of both MG and HD (see Fig. 1); by November 1996 no further therapy was necessary. Anti-AChR-ab progressively decreased to 1 pmol/ml in December 1998 (see Figure). In June 2003, while no signs or symptoms of MG and HD were present, the patient developed an intractable cough; a lung adenocarcinoma was soon diagnosed and 1 month later she died for heart failure.
Literature
1.
go back to reference Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Failace G (1994) ‘Extended’ thymectomy without sternothomy, performed by cervicothomy and thoracoscopic technique in the treatment of myasthenia gravis. Int Surg 79:38–381 Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Failace G (1994) ‘Extended’ thymectomy without sternothomy, performed by cervicothomy and thoracoscopic technique in the treatment of myasthenia gravis. Int Surg 79:38–381
2.
go back to reference Engel AG (1994) Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1769–97 Engel AG (1994) Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1769–97
3.
go back to reference Muller-Hermelink HK, Marx A, Kirchner T (1996) Thymus. In: Dùmianov I, Lindner J (eds) Anderson’s Pathology. St Louis, Mosby Year-Book, pp 1218–1243 Muller-Hermelink HK, Marx A, Kirchner T (1996) Thymus. In: Dùmianov I, Lindner J (eds) Anderson’s Pathology. St Louis, Mosby Year-Book, pp 1218–1243
4.
go back to reference Marx A, Muller-Hermelink HK (1999) From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of the Thimic Epithelial Tumors and related recent developments. Pathol Res Pract 195:515–533PubMed Marx A, Muller-Hermelink HK (1999) From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of the Thimic Epithelial Tumors and related recent developments. Pathol Res Pract 195:515–533PubMed
5.
go back to reference Null J, LiVolsi VA, Glenn WWL (1977) Hodgkin’s disease of the thymus (granulomatous thymoma) and myasthenia gravis. Am J Clin Pathol 67:521–525PubMed Null J, LiVolsi VA, Glenn WWL (1977) Hodgkin’s disease of the thymus (granulomatous thymoma) and myasthenia gravis. Am J Clin Pathol 67:521–525PubMed
6.
go back to reference Padua L, Palmisani MT, Di Trapani G, Evoli A, Larrocca LM, Tonali P (1994) Myasthenia gravis and thymic Hhodgkin’s disease associated in one patient with familial lymphoproliferative disorders. Clin Neuropathol 13:292–94 PubMed Padua L, Palmisani MT, Di Trapani G, Evoli A, Larrocca LM, Tonali P (1994) Myasthenia gravis and thymic Hhodgkin’s disease associated in one patient with familial lymphoproliferative disorders. Clin Neuropathol 13:292–94 PubMed
7.
go back to reference Tranchant C, Racamier E, Warter JM (1993) Seronegative myasthenia gravis and familial Hodgkin’s disease. Eur Neurol 33:17–19PubMed Tranchant C, Racamier E, Warter JM (1993) Seronegative myasthenia gravis and familial Hodgkin’s disease. Eur Neurol 33:17–19PubMed
8.
go back to reference Quilichini R, Fuentes P, Metge G, Lafeuillade A, Albatro J (1994) Syndrome myasthenique revelateur d’une maladie de Hodgkin. Rev Neurol (Paris) 150(1):81–82 Quilichini R, Fuentes P, Metge G, Lafeuillade A, Albatro J (1994) Syndrome myasthenique revelateur d’une maladie de Hodgkin. Rev Neurol (Paris) 150(1):81–82
9.
go back to reference Abrey LE, Askanas V (1995) Association of myasthenia gravis with extrathymic Hodgkin’s lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology 45:1019PubMed Abrey LE, Askanas V (1995) Association of myasthenia gravis with extrathymic Hodgkin’s lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology 45:1019PubMed
10.
go back to reference Aarli J. A. Clinical immunology of thymic tumors in patients with myasthenia gravis. In: Marx A, Muller-Hermelink HK (eds) Epithelial tumors of the thymus. Pathology, Biology, Treatment Plenum Press, New York, pp 265–269 Aarli J. A. Clinical immunology of thymic tumors in patients with myasthenia gravis. In: Marx A, Muller-Hermelink HK (eds) Epithelial tumors of the thymus. Pathology, Biology, Treatment Plenum Press, New York, pp 265–269
11.
go back to reference Bataller L, Dalmau J (2003) Paraneo-plastic neurologic syndromes: approaches to diagnosis and treatment Sem. Neurol 23(2):215–224 CrossRef Bataller L, Dalmau J (2003) Paraneo-plastic neurologic syndromes: approaches to diagnosis and treatment Sem. Neurol 23(2):215–224 CrossRef
12.
go back to reference Maggio E, Van der Berg A, Diepstra A, Kluiver J, Visser L, Popema S (2002) Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol 13:52–56PubMed Maggio E, Van der Berg A, Diepstra A, Kluiver J, Visser L, Popema S (2002) Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol 13:52–56PubMed
Metadata
Title
Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin’s disease
Authors
M. T. Ferrò
T. Riccardi
A. Montanelli
P. Bernasconi
R. Mantegazza
Publication date
01-09-2006
Publisher
Steinkopff-Verlag
Published in
Journal of Neurology / Issue 9/2006
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-006-0171-6

Other articles of this Issue 9/2006

Journal of Neurology 9/2006 Go to the issue

OriginalPaper

ENS COMMUNICATIONS